Litcius/Paper detail

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir

Yu Bai, Fei Ye, Yong Feng, Hanyi Liao, Hao Song, Jianxun Qi, George F. Gao, Wenjie Tan, Lifeng Fu, Yi Shi

2021Signal Transduction and Targeted Therapy38 citationsDOIOpen Access PDF

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Sars virusVirologyProtease2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)DrugProtease inhibitor (pharmacology)MedicinePharmacologyImmunologyBiologyEnzymeViral loadVirusPathologyBiochemistryInfectious disease (medical specialty)Antiretroviral therapyOutbreakDiseaseComputational Drug Discovery MethodsPharmacological Effects of Natural CompoundsSynthesis and biological activity
Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir | Litcius